Holen Sie sich die Stockscreener-App
43.05
1.69%
-0.74
Vorhandelsmarkt:
43.49
0.44
+1.02%
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Investors Purchase High Volume of Xenon Pharmaceuticals Call Options (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Aug Selloffs: Does Xenon Pharmaceuticals Inc stock have upside surprise potentialJuly 2025 Short Interest & Long Hold Capital Preservation Plans - baoquankhu1.vn
Xenon awaiting critical epilepsy drug study results that could lead to FDA approval - The Globe and Mail
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - Defense World
Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program - TipRanks
Xenon Pharmaceuticals registers $400M of common shares for ATM offering - TradingView
Xenon Pharmaceuticals (XENE) refreshes $400,000,000 ATM share program - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) registers up to $400M ATM equity offering - Stock Titan
Needham & Company LLC Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighWhat's Next? - MarketBeat
Wedbush Adjusts Xenon Pharmaceuticals PT to $47 From $44, Maintains Outperform Rating - marketscreener.com
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Finviz
Xenon Pharmaceuticals stock hits 52-week high at $46.68 - Investing.com
Xenon Pharmaceuticals stock hits 52-week high at $46.68 By Investing.com - Investing.com Canada
Westfield Capital Management Co. LP Boosts Stake in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative - Sahm
Decoding Xenon Pharmaceuticals Inc (XENE): A Strategic SWOT Insi - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Xenon Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Xenon Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
JPMorgan Chase & Co. Buys 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
XENE Technical Analysis & ETF Price Forecast - Intellectia AI
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Outperform Rating from Analysts at Wolfe Research - Defense World
Xenon earnings loom as investors brace for Phase 3 catalyst By Investing.com - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded at Wolfe Research - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Analyzing a 30% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
A Look At Xenon Pharmaceuticals (XENE) Valuation After Wolfe Research’s New Favorable Coverage - Yahoo Finance
Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating - Investing.com Nigeria
XENE: Xenon Pharmaceuticals Coverage Initiated by Wolfe Research - GuruFocus
Wolfe Research Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Investment Review: Will DRMA stock go up in YEAR2025 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Will Xenon Pharmaceuticals Inc. stock benefit from green energy trends2025 Fundamental Recap & Risk Controlled Daily Plans - mfd.ru
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index - Kalkine Media
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - Nasdaq
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - MarketBeat
Is Xenon Pharmaceuticals Inc. a speculative investmentJuly 2025 Rallies & Weekly Market Pulse Alerts - mfd.ru
Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Understanding Momentum Shifts in (XENE) - Stock Traders Daily
How Xenon Pharmaceuticals Inc. stock reacts to global recession fearsInsider Buying & Safe Swing Trade Setups - mfd.ru
Activity Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Is Xenon Pharmaceuticals Inc. stock a safe haven assetIPO Watch & Precise Swing Trade Entry Alerts - mfd.ru
Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
How Xenon Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Levels & Real-Time Price Movement Reports - mfd.ru
Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews
Is Xenon Pharmaceuticals Inc. a strong candidate for buy and holdPortfolio Gains Report & Fast Gaining Stock Reports - mfd.ru
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside - DirectorsTalk Interviews
Stifel raises Xenon Pharmaceuticals stock price target to $66 on XEN1101 potential - Investing.com Canada
Avoiding Lag: Real-Time Signals in (XENE) Movement - Stock Traders Daily
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Published on: 2026-02-04 12:37:47 - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: A Biotech Gem with 33.91% Upside Potential - DirectorsTalk Interviews
Published on: 2026-02-02 18:11:01 - baoquankhu1.vn
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):